2. Search Result
Search Result
Results for "

ATC

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

1

Recombinant Proteins

6

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-50867
    Lestaurtinib
    4 Publications Verification

    CEP-701; KT-5555

    		 JAK FLT3 Trk Receptor Apoptosis STAT Cancer
    Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC50s of 2, 25 and 0.9 nM for FLT3, TrkA and JAK2, respectively. Lestaurtinib induces apoptosis and cycle arrest, also can inhibit growth of tumor .
    Lestaurtinib
  • HY-150741
    ODN 2216
    1 Publications Verification

    		 Toll-like Receptor (TLR) IFNAR Interleukin Related Infection Inflammation/Immunology Cancer
    ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
    ODN 2216
  • HY-148511
    Vidutolimod

    CMP-001

    		 Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
    Vidutolimod
  • HY-107624
    ATC0175
    1 Publications Verification

    		 MCHR1 (GPR24) Neurological Disease
    ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC50s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders .
    ATC0175
  • HY-P9972
    Spartalizumab

    PDR001

    		 PD-1/PD-L1 IFNAR Cancer
    Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
    Spartalizumab
  • HY-145728
    Alicaforsen

    ISIS-2302

    		 Integrin Inflammation/Immunology
    Alicaforsen is an oligonucleotide and immunostimulant targeting human ICAM-1 mRNA. Alicaforsen hybridizes to specific sites to reduce the expression level of ICAM-1. Alicaforsen is applicable to relevant research on psoriasis, rheumatoid arthritis and inflammatory bowel disease .
    Alicaforsen
  • HY-15855
    Fosbretabulin tromethamine

    		Microtubule/Tubulin Cancer
    Fosbretabulin (tromethamine), also known as combretastatin A4 phosphate (CA4P), is a vascular disrupting agent evaluated for its efficacy against anaplastic thyroid carcinoma (ATC). It targets tumor neovasculature, causing acute and reversible reductions in tumor blood flow and central necrosis .
    Fosbretabulin tromethamine
  • HY-107626
    ATC0065

    		MCHR1 (GPR24) 5-HT Receptor Neurological Disease
    ATC0065 is a potent, selective and orally active melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist with an IC50 of 15.7 nM for human MCHR1. ATC0065 does not exhibits significant activity for MCHR2. ATC0065 has anxiolytic and antidepressant activities .
    ATC0065
  • HY-169387
    YT 6-2-PEG3-C2-NH2

    		AUTOTACs Cancer
    YT 6-2-PEG3-C2-NH2 is the p62/SQSTM1 targeting, autophagy-targeting ligand-linker conjugate of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .
    YT 6-2-PEG3-C2-NH2
  • HY-169385
    ATC-324

    		AUTOTACs Androgen Receptor Cancer
    ATC-324 is an bivalent AR (Androgen Receptor) degrader based on the protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 induces the formation of AR/p62 complex, leading to autophagy-lysosomal degradation of AR. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa . ATC-324 is composed of target-binding ligand (TBL) Enzalutamide (HY-70002) and p62/SQSTM1 autophagy-targeting ligand (ATL) YT 6-2 analog-1 (HY-169386), connected by Boc-NH-PEG4-CH2CH2NH2 (HY-W008352). Among them, the active control of the target protein ligand is Enzalutamide carboxylic acid (HY-70002B), and the conjugate composed of the autophagy-targeting ligand and the linker is YT 6-2-PEG3-C2-NH2 (HY-169387).
    ATC-324
  • HY-107626A
    ATC0065 free base

    		MCHR1 (GPR24) 5-HT Receptor Neurological Disease
    ATC0065 free base is a potent, selective and orally active melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist with an IC50 of 15.7 nM for human MCHR1. ATC0065 free base does not exhibits significant activity for MCHR2. ATC0065 free base has anxiolytic and antidepressant activities .
    ATC0065 free base
  • HY-169388
    YT 6-2

    		AUTACs Cancer
    YT 6-2 is the p62/SQSTM1 targeting, autophagy-targeting ligand (ATL) of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .
    YT 6-2
  • HY-14815
    Fosbretabulin

    Combretastatin A4 phosphate

    		 Apoptosis Microtubule/Tubulin Cancer
    Fosbretabulin (Combretastatin A4 phosphate) is a vascular disruptor with antitumor activity against atypical thyroid carcinoma (ATC) cell lines and xenografts. Fosbretabulin inhibits tumor growth by inhibiting microtubule polymerization, inducing apoptosis, and suppressing angiogenesis in tumors .
    Fosbretabulin
  • HY-116031
    ATC0175 free base

    		MCHR1 (GPR24) Metabolic Disease
    ATC0175 (free base) is a potent and selective antagonist of melanin-concentrating hormone receptor 1 (MCH-R1) with an IC50 value of 3.4 nM, as well as good selectivity over the Y5 and the α2A receptors. ATC0175 (free base) is promising for research of obesity .
    ATC0175 free base
  • HY-169386
    YT 6-2 analog-1

    		AUTOTACs Cancer
    YT 6-2 analog-1 (compound 2-3) is the p62/SQSTM1 targeting, autophagy-targeting ligand (ATL) of AUTOTAC ATC-324 (HY-169385), which is an bivalent AR (Androgen Receptor) degrader. ATC-324 can reduce nuclear AR levels and downregulate target gene expression of AR and AR-v7, and also has a degradation effect on common AR mutants in PCa .
    YT 6-2 analog-1
  • HY-RS01160
    ATM Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    ATM Human Pre-designed siRNA Set A contains three designed siRNAs for ATM gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    ATM Human Pre-designed siRNA Set A
    ATM Human Pre-designed siRNA Set A
  • HY-183102
    ATC12

    		Aurora Kinase Apoptosis Cancer
    ATC12 is a Aurora-A kinase inhibitor. ATC12 binds to Aurora-A and competes with TPX2 for binding to disrupt the Aurora-A/TPX2 interaction. ATC12 inhibits cancer cell proliferation, induces apoptosis and cellular senescence. ATC12 can be used in the research of breast cancer .
    ATC12
  • HY-107624R
    ATC0175 (Standard)

    		Reference Standards MCHR1 (GPR24) Neurological Disease
    ATC0175 (Standard) is the analytical standard of ATC0175 (HY-107624). This product is intended for research and analytical applications. ATC0175 is a potent, selective and orally active melanin-concentrating hormone 1 recepter antagonist with IC50s of 13.5, >10000 nM for MCH1R, MCH2R, respectively. ATC0175 shows antidepressant effects and anxiolytic effects in animal models. ATC0175 has the potential for the research of depression and/or anxiety disorders .
    ATC0175 (Standard)
  • HY-N19727
    Chamissonolide

    		Interleukin Related IFNAR TNF Receptor Apoptosis Infection Cancer
    Chamissonolide is a sesquiterpene lactone with cytotoxic, anti-inflammatory and trypanocidal activities. Chamissonolide reduces the mRNA levels of IL-2, IFN-γ, GM-CSF, iNOS and TNF-α, and upregulates the mRNA level of NF-ATc. Chamissonolide decreases the population of naturally occurring apoptotic cells. Chamissonolide can be used in research related to tumors, African trypanosomiasis and Chagas disease .
    Chamissonolide
  • HY-183637
    E822-1968

    		Urea Transporter Cardiovascular Disease Metabolic Disease Endocrinology
    E822-1968 is an UT-A2 inhibitor with a human IC50 of 0.44 μM. E822-1968 blocks urea transport mediated by UT-A2. E822-1968 can be used for the study of hyponatremia and edema associated with congestive heart failure, nephrotic syndrome, and cirrhosis .
    E822-1968

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: